Funding profile · Oncology AI

Triomics

Two announced venture rounds totalling $37 million, one Form D on file, and a Series B that has produced no Regulation D notice at all.

$22.0MSeries B led by Battery Ventures, announced May 28, 2026
$13.75MSold of $14.14M offered, the only Form D on file
10Investors in that offering, about $1.38M each
$36M+Total raised to date, company-reported

Data as of September 22, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
Dec 2022 to Feb 2023 Equity offering, Rule 506(b) $14,135,000 offered; $13,754,980 sold 10 investors, not named in the filing Form D
May 9, 2024 Series A, as announced $15M Lightspeed, Nexus Venture Partners, General Catalyst, Y Combinator Independent
May 28, 2026 Series B $22M Battery Ventures (lead); Nexus, Lightspeed, Y Combinator; Oncology Ventures; Precision Health Informatics Release, confirmed in reporting
To date Federal grants None found No NIH or NSF award Not found

What the filings show

Triomics, Inc. · Form D · filed Feb 22, 2023

First sale
Dec 12, 2022
Offered
$14,135,000 equity
Sold
$13,754,980 · $380,020 remaining
Investors
10 · average about $1,375,498
Exemption
Rule 506(b)
Issuer
Delaware corporation, incorporated 2021, San Francisco offices
Related persons
Sarim Khan (executive officer, director); Hrituraj Singh (director); Sameer Brij Verma (director); Sajjan Rajpurohit (director); Devtosh Kumar Khare (director)
Filing
SEC EDGAR, CIK 0001962627

Reading the filings

  1. The Series A was largely closed before it was announced.The Form D records a first sale on December 12, 2022 and was filed February 22, 2023. The company announced a $15 million Series A on May 9, 2024, about 15 months later. The $14,135,000 offered sits within $865,000 of that number. Either the filing covers that round, in which case the news was old when it broke, or a separate $15 million round carried no Regulation D notice.
  2. Ten checks, about $1.38 million each.$13,754,980 divided by 10 investors is $1,375,498 apiece, institutional sizing consistent with the four firms later named. The filing names no investor, only five related persons.
  3. The Series B has no Form D.A notice is due within 15 days of first sale. As of September 22, 2026, almost four months after the announcement, EDGAR shows one filing under CIK 0001962627. An issuer selling under Section 4(a)(2) files nothing, so the silence does not mean the round failed to close. It does mean the $22 million rests on the company release and reporting drawn from it.
  4. The filing contradicts itself on investor type.The issuer answered yes to selling to non-accredited investors, then put the number of non-accredited investors at zero. One answer is wrong, and no amendment has been filed.
  5. The board on file is investor-weighted.Three of the five related persons are neither founder: Sameer Brij Verma, a managing director at Nexus Venture Partners, plus Sajjan Rajpurohit and Devtosh Kumar Khare. Battery Ventures principal Brandon Gleklen joined with the 2026 round, which no filing reflects. The registered address is still San Francisco.
  6. No public money anywhere.No NIH grant, no NSF award, no FDA submission, no registered trial. For a company selling into NCI-designated cancer centers, the capital base is entirely private and the evidence base investigator-initiated or company-funded.

Commercial signals

Signal Detail Source type
Named customers MSK and Mount Sinai announced deployments under their own mastheads, Nov 2025 and Jan 2026. Yale leaders are quoted in a company release. MD Anderson and Texas Oncology are named only by the company. Customer release
Strategic investor Precision Health Informatics, a wholly owned Texas Oncology subsidiary, invested in the Series B. Texas Oncology is also a listed customer. Company release
Related party MSK discloses institutional financial interests related to Triomics, and its senior vice president for clinical research joined the company advisory board. Customer disclosure
Revenue Forbes put revenues comfortably into seven figures in June 2026. TechCrunch reported a fourfold rise in enterprise customers and a tenfold rise in annualized recurring revenue. Both trace to the CEO. Company-stated
Published evidence One peer-reviewed paper, two ASCO abstracts, one journal pilot report, one arXiv preprint. Six of thirteen authors on the peer-reviewed paper are company employees. Public record

What to watch

  • A Form D for the Series B, or confirmation it used Section 4(a)(2).
  • An amendment correcting the non-accredited investor answer on the 2023 filing.
  • Whether the 2024 Series A is ever reconciled with the 2023 offering.
  • A revenue figure or customer count that does not come from the founders.
  • Whether the Texas Oncology investment is disclosed in future outcome studies.

The Triomics story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • FidoCure: Shared investor: Oncology Ventures. A tumor sequencing service that routes dogs with cancer toward human targeted therapy drugs, compounded to canine doses
  • Loop Health: Shared investor: General Catalyst. A Pune company that sells group health insurance as a licensed broker and employs its own doctors to deliver the everyday care those policies do not cover
  • Modern Health: Shared investor: Battery Ventures. An employer-bought mental health benefit that sorts staff into coaching, therapy or self-guided content
  • Medinas Health: Shared investor: General Catalyst. A cloud based marketplace and software platform that helped hospitals value, redeploy and resell their surplus medical equipment

Sources

  1. Public recordForm D, Triomics, Inc., CIK 0001962627SEC EDGAR · Feb 22, 2023
  2. Public recordEDGAR filing index, CIK 0001962627SEC · Sep 22, 2026
  3. IndependentTriomics nabs $22M to bring oncology AI to cancer centersTechCrunch · May 27, 2026
  4. IndependentHow Triomics uses AI to help doctors treat cancer more quicklyForbes · Jun 3, 2026
  5. IndependentWhere participation in cancer trials lacks, Triomics could step inFierce Healthcare · May 10, 2024
  6. CompanyTriomics raises $22 millionPR Newswire · May 28, 2026
  7. CustomerMSK to deploy Triomics’ platformMemorial Sloan Kettering · Nov 4, 2025
  8. CustomerMount Sinai launches AI trial-matching platformMount Sinai Health System · Jan 8, 2026
  9. Public recordPRISM, competing interests statementnpj Digital Medicine · Oct 28, 2024

Compiled from SEC and other public records and published reports as of September 22, 2026. Form D notices report offerings under Regulation D; amounts reflect the filing date. Healthcare Venture Capital Fund holds no position in Triomics. This page is not an offer to sell or a recommendation to buy any security.